Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
Clinical trial NCT02513472 · COMPLETED
Trial details
- NCT number
- NCT02513472
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-28
- Primary completion
- 2019-07-31
- Enrollment
- 258
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.